Research Article
[Retracted] Effect of Tumor Microenvironment and Angiogenesis on Clinical Outcomes of Primary Central Nervous System Lymphoma
Table 4
Clinical and genomic characteristics of study population according to subsequent SubRT, ROBO1, and KAT2B somatic mutation status.
| Characteristic | No SubRT+mutated () | SubRT +nonmutated () | No SubRT+nonmutated () | value |
| AGE () | | | | 0.500 | SEX (male) | 1 (50.0%) | 5 (83.3%) | 2 (20.0%) | 0.027 | ROBO1 | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0.007 | KAT2B | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0.007 | APBA1 | 1 (50.0%) | 0 (0.0%) | 1 (10.0%) | 0.314 | GNA13 | 1 (50.0%) | 1 (16.7%) | 0 (0.0%) | 0.085 | MYD88 | 2 (100.0%) | 1 (16.7%) | 3 (30.0%) | 0.193 | SETD1B | 1 (50.0%) | 0 (0.0%) | 1 (10.0%) | 0.314 | IniRT | 0 (0.0%) | 0 (0.0%) | 2 (20.0%) | 0.608 | IniST | 1 (50.0%) | 6 (100.0%) | 6 (60.0%) | 0.212 | SubRT | 0 (0.0%) | 6 (100.0%) | 0 (0.0%) | <0.001 | SubST | 0 (0.0%) | 2 (33.3%) | 1 (10.0%) | 0.669 | OS | 1 (50.0%) | 6 (100.0%) | 9 (90.0%) | 0.314 |
|
|
value is estimated using the Wilcoxon rank-sum test or Fisher’s exact test. |